In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Grupo Farmaceutico Somar

gruposomar.com

Latest From Grupo Farmaceutico Somar

Biopharma Quarterly Deal-making Statistics, Q4 2017

Biopharma financing finished off 2017 strong with a total value of $14.5 billion in Q4, led again by FOPOs. CVS' massive $77 billion acquisition of Aetna resulted in an all-time quarterly high in the M&A category, and the largest alliances were dominated by the development of vaccines and antibodies.

Deals Market Intelligence

Opana ER Withdrawal Adds Weight To Endo's Ongoing Revenue Decline

With Endo's announcement July 6 that it will conform with FDA's request to remove Opana ER from the market, the specialty firm's prospects seem tied even more tightly to its generics business.

Drug Safety Business Strategies

Deals Shaping The Medical Industry, October 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced August-September 2014.

BioPharmaceutical Medical Device

Deals Shaping The Medical Industry, July/August 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced May and June 2014.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Mexico
  • Parent & Subsidiaries
  • Grupo Farmaceutico Somar
  • Senior Management
  • Jose M Ramos R, Chief Executive Officer
  • Contact Info
  • Grupo Farmaceutico Somar
    Phone: 55 53 40 23 55
    Adolfo Prieto 1427
    Mexico City,
    Mexico
Advertisement
Advertisement
UsernamePublicRestriction

Register